Moreover, this research identified the potential predictive biomarkers and novel vulnerabilities for therapeutic targeting, which will facilitate the clinical development of NK‐1R antagonists for newly diagnosed and relapsed human CRC. This evidence concerns the gene TACR1 and colorectal carcinoma.